Abstract:Custom RNA base editing using the endogenous human Adenosine Deaminase Acting on RNA (ADAR) enzyme presents a promising approach for precision therapeutics, alleviating concerns of permanent DNA damage or immunogenicity from foreign bacterial proteins such as CRISPR/Cas. ADAR can be directed to act on therapeutic RNA targets by antisense guide RNAs (gRNAs) that create a substrate for ADAR′s adenosine-to-inosine (effectively A-to-G) deamination activity. Delivery of gRNAs via a DNA expression construct provided by Adeno-Associated Virus (AAV) might allow life-long duration of the therapy. However, a major challenge for RNA editing using gene-encoded gRNAs and endogenous levels of ADAR is achieving sufficient gRNA activity inside cells, especially in therapeutic situations where AAV delivery may provide as low as one viral genome per cell. Here we show that embedding antisense gRNAs into a U7 small nuclear RNA (snRNA) framework and adding hnRNP A1 binding domains greatly increases the efficiency of custom RNA editing. This increased editing efficiency allows for detectable RNA editing from a single genomic insertion of gRNA construct per cell, which enabled a pooled library screen of 750+ gRNA variations to further improve the SmOPT U7 hairpin system. The screen revealed critical residues responsible for RNA editing and generated new SmOPT and U7 hairpin variants that further boosted RNA editing. The final design, combined with an improved synthetic U7 promoter, resulted in up to 76% targeted editing with a single integrated copy of construct per cell, representing a 10- to 100-fold increase over existing circular gRNA approaches. Using systemic AAV delivery, we achieved an unprecedented 75% RNA editing in the total brain of a mouse model of Hurler syndrome. Our novel SmOPT U7 system also improved published antisense oligos for DMD exon skipping, currently in clinical trials, by up to 25-fold in differentiated myoblasts, and therefore represents a universal scaffold for ADAR-based RNA editing as well as other antisense RNA therapies.

Engineered IscB-ωRNA system with improved base editing efficiency for disease correction via single AAV delivery in mice

Engineered IscB-ωRNA system with expanded target range for base editing

Engineering IscB to develop highly efficient miniature editing tools in mammalian cells and embryos

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Engineering APOBEC3A deaminase for highly accurate and efficient base editing

Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Utilizing AAV-mediated LEAPER 2.0 for Programmable RNA Editing in Non-Human Primates and Nonsense Mutation Correction in Humanized Hurler Syndrome Mice.

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo

A Novel Engineered U7 Small Nuclear RNA Scaffold Greatly Increases and ADAR-Mediated Programmable RNA Base Editing

Compact RNA editors with natural miniature Cas13j nucleases

An All-in-one AAV Vector for Cardiac-Specific Gene Silencing by an Adenine Base Editor

Imperfect guide-RNA (igRNA) enables CRISPR single-base editing with ABE and CBE

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

RNA base editing therapy cures hearing loss induced by OTOF gene mutation.

Efficient Gene Editing in Adult Mouse Livers Via Adenoviral Delivery of CRISPR/Cas9.

Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope

Robust RNA editing via recruitment of endogenous ADARs using circular guide RNAs